Danielle M. Brander, MD

Closing the OncLive News Network discussion, Danielle M. Brander, MD, of Duke University School of Medicine, asks Marc J. Braunstein, MD, PhD, of NYU Grossman Long Island School of Medicine, for the limitations clinicians should keep in mind when weighing infection risk between regimens in chronic lymphocytic leukemia (CLL) and for a single takeaway.

Danielle M. Brander, MD, of Duke University School of Medicine, asks how much weight to give real-world and comparative effectiveness data on infection risk in chronic lymphocytic leukemia (CLL), noting that trials do not answer every question and that cross-trial comparison should be avoided.

Danielle M. Brander, MD, of Duke University School of Medicine, compares infection rates across covalent Bruton tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia (CLL).

Danielle M. Brander, MD, of Duke University School of Medicine, notes that long-term CLL14 follow-up in chronic lymphocytic leukemia (CLL) showed a median progression-free survival of about 76 months with venetoclax plus obinutuzumab overall but roughly 64 months in unmutated IGHV disease and 49 to 50 months with TP53 aberrations.

Danielle M. Brander, MD, of Duke University School of Medicine, summarizes the CLL14 trial in chronic lymphocytic leukemia (CLL), which randomized patients to chlorambucil plus obinutuzumab or fixed-duration venetoclax plus obinutuzumab given for about 12 months.

Danielle M. Brander, MD, of Duke University School of Medicine, turns to the ELEVATE-TN trial in chronic lymphocytic leukemia (CLL), which compared continuous acalabrutinib monotherapy with acalabrutinib plus 6 cycles of obinutuzumab.

Danielle M. Brander, MD, of Duke University School of Medicine, reviews infection data from the AMPLIFY trial in chronic lymphocytic leukemia (CLL), which randomized patients to chemoimmunotherapy, acalabrutinib plus venetoclax, or acalabrutinib plus venetoclax plus obinutuzumab.

Danielle M. Brander, MD, of Duke University School of Medicine, outlines frontline options in chronic lymphocytic leukemia (CLL), continuous Bruton tyrosine kinase (BTK) inhibitors with or without anti-CD20 antibodies versus fixed-duration venetoclax plus obinutuzumab, and asks what immune recovery looks like once fixed-duration therapy ends.

Marc J. Braunstein, MD, PhD, of NYU Grossman Long Island School of Medicine, walks Danielle M. Brander, MD, of Duke University School of Medicine, through the immune defects intrinsic to chronic lymphocytic leukemia (CLL).

Danielle M. Brander, MD, of Duke University School of Medicine, opens the discussion with Marc J. Braunstein, MD, PhD, of NYU Grossman Long Island School of Medicine, on infection as a competing risk in chronic lymphocytic leukemia (CLL).

Danielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses targeted agents in chronic lymphocytic leukemia (CLL).

Danielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the safety and efficacy of the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL).

Danielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the frontline treatment of patients with chronic lymphocytic leukemia.

Danielle Marie Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment landscape for patients with high-risk chronic lymphocytic leukemia (CLL).